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The cyclin-dependent kinase (CDK) inhibitor p27kip1 is a critical
regulator of the G1/S-phase transition of the cell cycle and also
regulates microtubule (MT) stability. This latter function is exerted
by modulating the activity of stathmin, an MT-destabilizing protein,
and by direct binding to MTs. We recently demonstrated that in-
creased proliferation in p27kip1-null mice is reverted by concomitant
deletion of stathmin in p27kip1/stathmin double-KO mice, suggesting
that a CDK-independent function of p27kip1 contributes to the control
of cell proliferation. Whether the regulation of MT stability by p27kip1
impinges on signaling pathway activation and contributes to the de-
cision to enter the cell cycle is largely unknown. Here, we report that
faster cell cycle entry of p27kip1-null cells was impaired by the con-
comitant deletion of stathmin. Using gene expression profiling cou-
pled with bioinformatic analyses, we show that p27kip1 and stathmin
conjunctly control activation of the MAPK pathway. From amolecular
point of view, we observed that p27kip1, by controlling MT stability,
impinges on H-Ras trafficking and ubiquitination levels, eventually
restraining its full activation. Our study identifies a regulatory axis
controlling the G1/S-phase transition, relying on the regulation of
MT stability by p27kip1 and finely controlling the spatiotemporal
activation of the Ras-MAPK signaling pathway.
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In multicellular organisms, each cell responds to external stimuliby finely modulating, in time and space, the activation of in-
tracellular signal transduction pathways (1). Microtubules (MTs)
represent one of the preferential networks involved in the or-
dered propagation of this information within the cell. MTs are
organized into a polarized array that defines cellular polarity and
serves to directionally transmit extra- to intracellular signals, and
vice versa (2). MT functions are strictly linked to MT stability
and dynamics, which govern signaling compartmentalization; ac-
tivation levels of signal transduction pathways; and, consequently,
several cellular processes, including cell cycle progression (2, 3).
In particular, passage through the restriction point represents the
prototype of a cellular process in which ordered integration of
external and internal stimuli is strictly required (4).
A prominent role in this integrated system of growth control
has been ascribed to the Ras-MAPK pathway (5). Ras is a small
guanosine triphosphatase (GTPase) that localizes to the membrane
and requires recycling in the vesicle compartment to be fully acti-
vated (6, 7). Full activation of the Ras-MAPK pathway results in
ERK1/2 nuclear translocation and expression of specific transcrip-
tion factors, such as EGR-1, Jun-B, and c-Fos (8). The regulation of
this pathway by MTs has been proposed, but the molecular mech-
anisms have never been elucidated (2).
The Ras-MAPK cascade directly signals on two key regulators
of cell cycle entry, namely, cyclin D1 and p27kip1 (9). Cyclin D1 is
transcribed following Ras-MAPK pathway activation, and the ab-
erration of this molecular event underlies Ras-driven carci-
nogenesis (9, 10). Phosphorylation of p27kip1 (hereafter p27)
on Ser-10, following Ras-MAPK pathway activation, impinges on its
stability and subcellular localization, and has been proposed to play
a central role in Ras-driven tumorigenesis (11, 12).
We have recently demonstrated that p27 and stathmin genet-
ically interact in vivo and that this interaction impinges on cell
proliferation, eventually leading to organ size determination (13).
Interestingly, both p27 and its interacting partner stathmin are im-
plicated in the regulation of MT stability, with p27 acting as an MT
stabilizer and stathmin acting as an MT destabilizer (14–17).
Here, we investigated in vitro and in vivo the role of p27/stathmin
interaction in cell proliferation. Our findings unveil a regulatory axis
controlling the G1/S-phase transition in mammalian cells, relying
on the regulation of MT stability by p27 and eventually mod-
ulating the spatiotemporal activation of the Ras-MAPK signal-
ing pathway.
Results
Stathmin Is Necessary for the Hyperproliferative Phenotype of p27
Null Primary Fibroblasts. In vivo, the proliferation-related pheno-
types of p27-null animals are partially reverted by concomitant
KO of stathmin (13). To understand the molecular mechanisms
underlying this reversion, we generated primary mouse embry-
onic fibroblasts (MEFs) from WT, p27KO, stathmin KO (StmKO),
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and p27KO-StmKO [hereafter called double-KO (DKO)] mice and
studied their proliferative behavior in vitro. Growth curve analyses
demonstrated that DKO MEFs grew at an intermediate rate be-
tweenWT and p27-null cells (Fig. 1A). BrdU incorporation (Fig. 1B)
and TUNEL assays (Fig. 1C) indicated that the differences between
p27KO and DKO MEFs were due to increased proliferation, rather
than decreased apoptosis. No differences were observed between
WT and StmKO MEFs (Fig. 1 A–C), which, accordingly, increased
their number twofold in 4 days of culture (n = 5; WT = 1.96 ± 0.18,
StmKO = 1.86 ± 0.20) (Fig. 1D). In the same time, p27KO MEFs
increased about fourfold and DKOMEFs displayed an intermediate
phenotype, increasing 2.8-fold (Fig. 1D). The same differences were
also observed when MEFs were generated from different genetic
backgrounds (SI Appendix, Fig. S1A). Overexpression of stathmin in
WT, but not in p27KO, 3T3 fibroblasts led to an increase of their
proliferation (SI Appendix, Fig. S1B), supporting the possibility that
stathmin actively participated in the control of cell proliferation in a
p27-dependent manner.
p27 Controls Cyclin-Dependent Kinase 2 Activity in a Stathmin-
Independent Manner. Based on these results, we focused on the
study of cell cycle progression in WT, p27KO, and DKO MEFs. In
exponentially growing conditions, p27-null cells displayed a slight
increase in S-phase population, compared with both WT and DKO
cells (SI Appendix, Fig. S1C, Upper). Nevertheless, all tested primary
MEFs responded similarly to contact inhibition (SI Appendix, Fig.
S1C, Lower; high confluence), as already reported (18), suggesting
that the differences in cell proliferation were not due to different
ability to exit from the cell cycle.
The increased proliferation rate observed in p27-null cells and
mice has been largely ascribed to increased cyclin-dependent
kinase 2 (CDK2) and CDK1 activity (18–20). Similar to what we
recently observed in vivo (13), p27KO cells displayed higher
CDK2-, cyclin A-, and cyclin B1-associated kinase activities with
respect toWT, but not DKO,MEFs (SI Appendix, Fig. S1D and E).
However, DKO cells showed decreased CDK4 activity with respect
to p27KO cells (SI Appendix, Fig. S1D). Although stathmin is a
substrate for both CDK2 and CDK1 (15, 21, 22), increasing doses of
recombinant stathmin did not have an impact on the kinase activity
of either endogenous or recombinant protein complexes (SI Ap-
pendix, Fig. S2 A and B).
Overall, our data confirm that the higher CDK2 activity observed
in p27-null cells is not sufficient to explain their increased pro-
liferation rate, as also proposed by others (19, 20).
p27/Stathmin Interaction Regulates Cell Cycle Entry. The above data
suggested that G1/S-phase progression could be affected by stath-
min loss in the absence of p27. Consistently, following serum
stimulation, p27KO cells entered into S phase ∼4 h earlier than
WT and DKO cells, showing an anticipated increase in cyclin A
expression (S-phase marker) and CDK2, as well as cyclin E-, cyclin
A-, and cyclin B1-associated kinase activities, with respect to both
WT and DKO MEFs (SI Appendix, Fig. S1 F–I). Accordingly,
overexpression of stathmin in WT fibroblasts resulted in a faster
G1/S-phase transition, whereas stathmin knockdown in p27KO
MEFs delayed cell cycle entry and cyclin A expression (SI Ap-
pendix, Fig. S3 A–C).
p27/Stathmin Interaction Regulates ERK1/2 Activity. To evaluate
whether the different proliferative behavior was linked to alter-
ation of specific pathways, we performed a microarray on MEFs
of the genotypes of interest. By this approach, we identified a
p27 signature comprising 263 genes differentially expressed
between WT and p27KO cells and a DKO signature com-
prising the genes, among the 263, reverted in DKO fibro-
blasts (n = 55) (SI Appendix, Fig. S4). As a proof of principle,
15 differentially regulated genes were validated in quantitative RT-
PCR analyses (SI Appendix, Fig. S4). Using the Gene Annotation
Tool to Help Explain Relationships (GATHER) resource (gather.
genome.duke.edu) and the Pathway-Express resource, linked to
the Kyoto Encyclopedia of Genes and Genomes (KEGG) database
(vortex.cs.wayne.edu/projects.htm), we identified the MAPK and
mammalian target of rapamycin (mTOR) signaling pathways as
significantly altered by p27 loss (SI Appendix, Tables S1 and S2).
Experimental testing of the bioinformatic results confirmed
that activation of ERK1/2 was increased in p27KO with respect to
both WT and DKO cells, whereas the mTOR pathway (using
pAKT, pp70S6K, and pS6 as readouts) was not differentially acti-
vated (Fig. 2A). These observations were recapitulated in time
course analyses (SI Appendix, Fig. S5A) and using different external
stimuli, such as stimulation with EGF or IGF-1 (SI Appendix, Fig.
S5B) or adhesion to ECM components (SI Appendix, Fig. S5C).
Activation of the ERK1/2 seemed to be specifically controlled by
p27/stathmin interaction, because it was decreased by reintro-
duction of p27WT in p27-null cells (Fig. 2B) and increased by
reintroducing stathmin in DKO cells (Fig. 2C). Increased activa-
tion of ERK1/2 in p27-null cells was followed by increased ex-
pression of MAPK pathway nuclear targets, Egr-1 and Jun-B,
both in p27KO MEFs and 3T3 fibroblasts (Fig. 2 D and E and
SI Appendix, Fig. S5D). These observations were recapitulated
in vivo, because both Jun-B and Egr-1 expression levels were
significantly higher in thymus and spleen from p27KO mice than
in respective organs from both WT and DKO mice (SI Appendix,
Fig. S5E). Taken together, our data indicated that the MAPK
pathway was consistently and robustly up-regulated in the absence
of p27 and that this phenotype was reverted by loss of stathmin,
both in vitro and in vivo.
p27 Regulates Activation of the MAPK Pathway in a CDK-Indepen-
dent Manner. It is well known that p27 exerts CDK-dependent
and -independent functions (14, 23). To understand whether lack
of inhibition of CDKs could be responsible for the higher activity
of ERK1/2 observed in p27-null cells, we treated p27KO MEFs
with roscovitine, a chemical inhibitor of CDK activity. Roscovi-
tine, used at a concentration able to inhibit CDK2 activity and
S-phase entry of p27KO cells, did not modify pERK levels in p27KO
cells (Fig. 3A and SI Appendix, Fig. S6 A–C) or the transcriptional
Fig. 1. Stathmin is necessary to sustain the proliferative phenotype of p27-
null MEFs. (A) Growth curves of MEF WT, p27KO, DKO (three different
embryos), and StmKO. Cells, plated on day 0, were counted at the indicated
time points by a Trypan blue exclusion test. BrdU incorporation (B) and TUNEL
(C) assays on exponentially growingMEF populations of the indicated genotypes
were performed. The percentage of positive cells is indicated. (D) Duplication
potential of MEF WT, p27KO, DKO, and StmKO cells, plated on day 0 and
counted at day 4. The fold increase in cell number in five different MEF prepa-
rations/genotypes is reported. In each graph, statistical significance is calculated
by the Student’s t test and expressed by P ≤ 0.05. ns, not significant.
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activation of the MAPK pathway target genes Egr-1, Jun-B, and
c-Fos (Fig. 3B and SI Appendix, Fig. S6 D and E). Conversely,
both events were strongly blocked by using a MEK1/2 inhibitor,
U0126 (Fig. 3 A and B and SI Appendix, Fig. S6 D and E). Next,
we transfected p27KO fibroblasts with the p27CK− mutant, which
is unable to bind and inhibit the cyclin/CDK complexes, or with
the p27KR mutant, which is prevalently localized in the cytoplasm
(24). Both mutants exerted effects similar to the effects of the
p27WT protein (Fig. 3C and SI Appendix, Fig. S6 F and G), in-
dicating that MAPK pathway regulation is a cytoplasmic and CDK-
independent function of p27.
Hyperactivation of the MAPK Pathway Is Responsible for the Faster
Cell Cycle Entry of p27KO Cells. Sustained pERK levels and Egr-1
expression are critical events for cell cycle entry (5, 9). In line with
these notions, we observed that inhibition of MAPK signaling, using
the U0126 inhibitor, prevented the faster cell cycle entry of p27KO
MEFs (Fig. 4A).
The MAPK pathway controls the G1/S transition by inducing
cyclin D1 transcription and by delocalizing and favoring p27 deg-
radation (9, 14), suggesting that in p27 null cells, the increased
MAPK signaling would primarily have an impact on cyclin D1 ex-
pression. We tested this hypothesis by evaluating levels of cyclin D1
mRNA and protein in cells starved and then serum-stimulated. Our
results showed that cyclin D1 levels increased 2 h earlier in p27KO
cells compared with WT and DKO cells SI Appendix, Fig. S6 H and
I). This effect was specifically dependent on MAPK activation,
because it was reverted by the use of U0126 (SI Appendix, Fig.
S6H). In line with these results, use of a specific inhibitor of CDK4/
6 activity (PD0332991) (Fig. 4A) or silencing of cyclin D1 (Fig. 4B)
resulted in delayed S-phase entrance of p27KO cells. Overall, these
data suggested that p27 regulates the G1/S transition, at least
in part, via the activation of the MAPK pathway in a stathmin-
dependent manner.
MT-Dependent Transport Is Required for the Higher ERK1/2 Activation
Observed in p27KO Cells. Endocytosis and endocytic trafficking
are processes that rely on MTs and are strongly implicated in
transmitting signals originating from the outside of the cell, and vice
versa. Therefore, we tested whether p27/stathmin interaction could
regulate MAPK pathway activation acting on these processes. To
this aim, WT, p27KO, and DKOMEFs were stimulated with serum
Fig. 2. Interaction of p27/stathmin regulates MAPK pathway activation. (A) Western blot analysis of the mTOR and MAPK pathway activation in WT and
p27KO MEFs that were serum-starved and then stimulated with 10% serum (FBS) for the indicated times. Western blot analysis of pERK1/2 and pAKT in 3T3
fibroblasts of the indicated genotypes and 3T3 p27KO stably reexpressing p27 (B) or 3T3 DKO stably reexpressing stathmin (C) was performed. Cells were
serum-starved and then stimulated with FBS for the indicated times. Numbers at the bottom of the panels indicate the quantification of normalized (Norm.)
ERK1/2 phosphorylation levels. Quantitative RT-PCR analysis of Egr-1 in MEFs (D) or 3T3 fibroblasts (E) that were serum starved and then stimulated with 10%
serum (FBS) for the indicated times. A.U., arbitrary units.
Fig. 3. p27 controls MAPK activation in a CDK-independent manner.
(A) Western blot analysis of pERK1/2 and pAKT expression in MEF p27KO cells
that were serum starved and then stimulated with 10% serum (FBS) for the in-
dicated times, in the presence or absence of the MEK1 inhibitor U0126 (U0) or
the pan-CDK inhibitor roscovitine (Ros, Rosco), as indicated. (B) Quantitative RT-
PCR (qRT-PCR) analysis of Egr-1 and Jun-B in p27KOMEFs treated as described in
A. *P ≤ 0.007. (C) qRT-PCR analysis of Egr-1 and Jun-B in 3T3 fibroblasts of the
indicated genotypes and in 3T3 p27KO cells stably expressing p27WT, p27CK−, or
p27KR. Cells were serum-starved and then stimulated with 10% serum (FBS) for
the indicated times. *P ≤ 0.04.
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in the presence or absence of dynasore, which inhibits dynamin
activity and prevents endocytosis (25), or low doses of taxol, an MT-
stabilizing drug. Both compounds significantly decreased the extent
of ERK1/2 phosphorylation (SI Appendix, Fig. S7A) and the
transcription of its downstream targets Egr-1, c-Fos, and Jun-B
(SI Appendix, Fig. S7 B–D). Accordingly, treatment with dynasore
completely prevented cell cycle entry in serum-stimulated MEFs
and 3T3 fibroblasts (SI Appendix, Fig. S7 E and F).
A skin wound-healing assay represents a paradigm for growth
factor-induced spatiotemporal regulation of cell cycle entry in vivo,
and it is associated with stathmin up-regulation (26) and p27 down-
regulation (27). We performed this assay in p27KO mice, treating
them or not with taxol for 48 h (n = 4 per group), to evaluate
whether induction of MT stabilization in the p27KO context was
accompanied by a decrease in cell cycle entry. As expected, taxol-
treated mice displayed increased MT stabilization in cells facing
the wound, as evaluated by the levels of acetylated tubulin
(Fig. 4C, red). Interestingly, this MT stabilization was ac-
companied by a decrease of cell proliferation, as assessed by
Ki67 staining (Fig. 4C, green).
To evaluate whether vesicle internalization and/or transport
was altered by loss of p27, we used different approaches. First,
we transfected WT and p27KO cells with dynamin1K44A, a
dynamin mutant that exerts a dominant negative effect on endo-
cytosis (28). Overexpression of dynamin1K44A significantly inhibited
ERK activation in both WT and p27KO cells (Fig. 4 D and E),
leaving the relative difference between the two cell types intact. On
the contrary, impairment of vesicle transport by temperature shift-
ing from 37 °C to 18 °C or 4 °C (6) prevented hyperactivation of
MAPK in p27KO cells (SI Appendix, Fig. S8A), abolishing the dif-
ference between WT, p27KO, and DKO cells.
Vesicles and other intracellular cargos are transported along
the MTs by kinesin- and dynein-motor proteins (29). Blocking
this transport using a dynein inhibitor, erythro-9-(2-Hydroxy-3-
nonyl)adenine (EHNA) hydrochloride (30), abolished serum-
induced ERK phosphorylation in p27KO cells and strongly reduced
it in WT cells, further indicating that p27KO cells were particularly
sensitive to impairment of MT-dependent transport for signaling
(Fig. 4 F and G and see SI Appendix, Fig. S8B).
p27 Inhibits H-Ras Activation via Stathmin. Data collected so far
failed to identify a specific external stimulus able to hyperactivate
the MAPK cascade in p27KO cells, suggesting that an intracellular
upstream activator should be involved. The canonical upstream
activator of the MAPK pathway is H-Ras, a small GTPase that
localizes to the membrane (6) and requires recycling in the vesicle
compartment to be fully activated (7). We thus investigated if
H-Ras activity and localization were differentially regulated in WT,
p27KO, and DKO cells. Serum stimulation induced a marked
GFP–H-Ras membrane localization in p27KO cells, with respect to
WT and DKO cells (Fig. 5A and SI Appendix, Fig. S9A). This ob-
servation was confirmed by confocal microscopy showing increased
plasma membrane localization (SI Appendix, Fig. S9A) and a de-
creased amount of GFP–H-Ras in Rab-5–positive vesicles in
p27KO cells, compared with WT or DKO cells (Fig. 5B). Rab-5 is
a small GTPase regulator of vesicular trafficking, and it is in-
volved in the mono- or biubiquitination of H-Ras (31), a process
resulting in decreased H-Ras activity (31, 32). We thus tested
whether H-Ras was differently mono- or biubiquitinated in the
presence/absence of p27 and stathmin. Expression of p27 in-
creased levels of H-Ras ubiquitination (Fig. 5 C and D and SI
Appendix, Fig. S9 B and C), and coexpression of stathmin almost
Fig. 4. Relative p27/stathmin expression levels control cell cycle progression via MT-dependent vesicle transport. (A) Percentage of S-phase in MEFs serum-
starved and stimulated with 10% FBS, with or without U0126 (U0) or PD0332991 (PD), for the indicated times. (B) Percentage of BrdU incorporation of 3T3
p27KO, silenced for cyclin D1 expression, serum-starved and then stimulated with 10% FBS for the indicated times. The probability value was calculated by the
Student’s t test. (Upper) Cyclin (Cyc) D1 expression in control (sh Cont) and silenced (sh Cyc D1) cells is reported. Vinculin was used as a loading control. sh,
short hairpin RNA. (C) Immunofluorescence analyses of Ki67 (green) and acetylated tubulin (Tub. Ac., red) in excisional wounds of the skin from p27KO mice
treated with vehicle (control) or taxol (5 mg/kg). Typical images from two different mice per group are shown. Nuclei are stained with propidium iodide
(pseudocolored in blue). (D) Immunofluorescence analyses of pERK1/2 (red) and F-actin (blue) in WT and p27KO fibroblasts, transfected with EGFP-
dynamin1K44A (DynK44A) mutant (green) and stimulated with 10% serum (FBS) for 15 min. (E) Graph reports the quantification of pERK1/2 staining shown in D. (F)
Immunofluorescence analyses of pERK1/2 (green) and F-actin (red) inWT and p27KO fibroblasts, treated or not with erythro-9-(2-Hydroxy-3-nonyl)adenine (EHNA)
hydrochloride and then stimulated with serum for 5 min. (G) Graph reports the quantification of pERK1/2 staining shown in F. In E and G, each dot in the graph
corresponds to one analyzed cell. Significant differences were calculated using the Mann–Whitney unpaired t test.
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completely reverted this effect (Fig. 5 C and D and SI Appendix,
Fig. S9 B and C).
To verify if H-Ras ubiquitination levels were specifically modu-
lated by p27/stathmin interaction, we used the p271–170 deletion
mutant, which lacks the last 28 amino acids and is unable to bind
and restrain stathmin activity (16, 33). Expression of p271–170 eli-
cited no effect on H-Ras ubiquitination (SI Appendix, Fig. S9C).
Consistently, endogenous H-Ras was less ubiquitinated in p27KO
MEFs than in WT and DKOMEFs (SI Appendix, Fig. S9 D and E).
In accord with the inhibitory role of ubiquitination on H-Ras ac-
tivity, we also observed increased activity of endogenous H-Ras in
p27KO MEFs (Fig. 5E) and mouse brains (SI Appendix, Fig. S9F),
compared with both WT and DKO counterparts.
To get some insights on how stathmin could participate in the
regulation of H-Ras activation, we investigated the localization of
stathmin following serum stimulation in WT and p27KO MEFs.
Serum stimulation induced a rapid membrane localization of
stathmin only in p27KO cells (SI Appendix, Fig. S10 A and B). This
localization was prevented by a temperature shift to 4 °C, indicating
that it represented an active process occurring in p27KO cells (SI
Appendix, Fig. S10 A and B, Right). Presence of stathmin at the
plasma membrane in p27KO cells was accompanied by a strong
decrease in the cellular pool of stable acetylated MTs, with respect to
what was observed in WT cells (SI Appendix, Fig. S10 C and D).
These data indicated that p27, via MT stabilization, regulated
H-Ras intracellular transport, eventually modulating its ubiq-
uitination and activity. However, we could not exclude the pos-
sibility that p27 acted in a more general fashion, reducing the
overall endocytic process. To approach this possibility, we verified
whether p27 affected the internalization of fluorophore-conjugated
transferrin and EGF, two commonly used markers of endosomal
trafficking. Overexpression of either p27WT or p271–170 had no ef-
fect on the rate of EGF internalization (SI Appendix, Fig. S11 A–C).
Similarly, absence of p27 did not change the internalization of
transferrin by 3T3 fibroblasts (SI Appendix, Fig. S11 D–F). These
data suggested that p27/stathmin interaction principally affected
vesicle transport, rather than internalization.
Altogether, our data demonstrate that loss of p27, by releasing
stathmin activity, alters H-Ras trafficking, diminishes its mono- or
biubiquitination, and results in hyperactivation of MAPK signal-
ing, which eventually contributes to anticipation of cell cycle entry.
Discussion
Signal transduction pathways need to be finely tuned and in-
tegrated in time and space to ensure that cells proliferate only in the
presence of appropriate extracellular and intracellular conditions
(1). Our data demonstrate that, following growth factor stimulation,
p27kip1 prevents full activation of H-Ras, modulating its trafficking
in an MT-dependent manner. This mechanism might represent a
useful strategy for a cell to prevent inappropriate proliferation. The
contribution of MTs in propagating intracellular signals is well
characterized (2). However, whether MTs and MT-dependent
transport have a role in the regulation of cell cycle entry has not
been clarified. A gradient of MT stabilization, due also to localized
stathmin activity, has been observed in migrating and mitotic cells,
and has been proposed as one of the main mechanisms by which an
organized flux of information is delivered within the cell (34). Our
data indicate that a similar mechanism participates in the regulation
of cell cycle entry and point to the spatial and temporal regulation
of H-Ras activity as a key event governed by MT stability and MT-
dependent transport. This finding is independently supported by
data recently reported by others (35), demonstrating that p27, by
regulating MT organization, contributes to control the trafficking of
Rab5-containing vesicles.
The central role of Ras proteins in driving proliferation, in
both normal and cancer cells, has been widely demonstrated (36).
The relevance of the cyclin D1/CDK4/6 complex and p27 expres-
sion in Ras-induced proliferation is also well established (8–10). In
Fig. 5. Interaction of p27/stathmin controls H-Ras localization and activation. (A) Immunofluorescence analysis of H-Ras (GFP, green) superimposed on the
reflection images of the same fields (gray, cell shape) in 3T3 WT, p27KO, and DKO fibroblasts that were serum-starved and stimulated with 10% serum (FBS)
for 15 min at 37 °C. (Right) Graph reports the quantification of H-Ras membrane localization (membr. loc.), expressed as fluorescence intensity at the plasma
membrane with respect to the total fluorescence of the cell. Each dot in the graph corresponds to one cell. Significant differences were calculated using the
Mann–Whitney t test. (B) Immunofluorescence analysis of H-Ras (GFP, green) and Rab5 (red) expression in 3T3 WT, p27KO, and DKO fibroblasts. (Right) Graph
reports the quantification of GFP–H-Ras in Rab-5–positive vesicles, expressed by the Pearson correlation coefficient. Significant differences were found using
the Mann–Whitney t test. (C) Immunoprecipitation analysis of H-Ras mono- or biubiquitination in 293T/17 cells, transfected with FLAG-tagged H-Ras in the
presence or absence of HA-tagged ubiquitin vector (HA-UB), Myc-tagged p27 vector, and EGFP-tagged stathmin vector, as indicated. Total cell lysates were
immunoprecipitated with an anti-FLAG antibody and probed with anti-HA or anti-FLAG antibodies, as indicated. Arrows indicate mono- (Mono-Ub) and
biubiquitinated (Bi-Ub) forms of H-Ras. Long exposure (LE) and short exposure (SE) of the same blot are shown. The arrowhead indicates unmodified FLAG-
tagged H-Ras. Asterisks mark light and heavy IgG chains. (D) Graph reports the amount of mono- and biubiquitinated H-Ras, obtained by densitometric
quantification of the blots in C, expressed as the fold increase of mono- or biubiquitination over the control (i.e., FLAG–H-Ras + HA-ubiquitin). Ctr, control.
(E) Pull-down assays of active Ras (GTP-loaded Ras) in lysates from MEFs of the indicated genotypes. Vinculin was used as a loading control. H-Ras activity,
normalized by H-Ras expression, is reported in the accompanying graph.
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accord with our data, the study performed on CDK4/p27 DKO and
CDK2/p27 DKO MEFs demonstrated that the faster entrance into
S phase of p27-null MEFs could be prevented by genetic ablation of
CDK4 (37), but not of CDK2 (19). Thus, our data, along with the
current literature, suggest that p27 plays a double role in the control
of cell proliferation by directly inhibiting CDK1 and CDK2 activity
and by controlling the full activation of the Ras-MAPK-CDK4/6
pathway, via the regulation of MT stability.
We suggest here that the cell cycle machinery directly partic-
ipates in the control of its upstream activator Ras-MAPK by
simply delocalizing p27 in the cytoplasm upon growth factor
stimulation. This mechanism could represent a fundamental check-
point to prevent inappropriate proliferation, ensuring that a cell ac-
tually divides only when mitogenic stimuli are sufficient to overcome
the threshold required to transit through the G1-S phase (5). Our
data suggest that the expression of cytoplasmic p27 is involved in the
control of this threshold. Similarly, it has been recently observed that
the cyclin A2/CDK2 complex can activate AKT, directly participating
in the control of its upstream activator (38).
The data presented here, conjunctly with the characterization
of the p27/stathmin DKO mouse (13), suggest that this mechanism
of control of cell cycle entry operates in multiple tissues, allowing
for proper development of the entire organism. Most of the
phenotypes of p27kip1-null mice, linked to the hyperproliferative
behavior of tissues and organs, were efficiently reverted by co-
ablation of stathmin (13). On the contrary, StmKO mice did not
display an overt proliferation-related phenotype (13, 39) and were
as sensitive as WT animals to chemically induced tumorigenesis
(39), suggesting that, in the presence of p27, other mechanisms can
compensate for the effects of stathmin on cell proliferation.
Altogether, we delineate here a previously unknown mechanism
involved in the control of cell cycle progression. Future research
will clarify if this knowledge can be exploited to block uncontrolled
proliferation in tumor cells, particularly in H-Ras–driven cancers.
Materials and Methods
Materials and methods are described in greater detail in SI Appendix.
Mice Models and Phenotypic Characterization. All animal procedures were ap-
proved by the Animal Care and Use Committee of the Centro di Riferimento
Oncologico Aviano. C57BL/6 p27KO mice (The Jackson Laboratory) and C57BL/6
StmKO mice (39) were intercrossed to obtain p27 and stathmin DKO C57BL/6
mice. Mice have been thoroughly characterized by Berton et al. (13).
Cell Cultures. The primary WT, p27KO, StmKO, and p27/stathmin DKO MEFs
were prepared from embryos at day 13.5, according to standard procedures,
as described (16, 40, 41). The 3T3 fibroblasts were obtained from primary
MEFs using the 3T3 immortalization protocol (16, 40, 41).
Proliferation, Apoptosis, and Ras Pull-Down Assays. Analyses of cell pro-
liferation by growth curves, MTS assay (Promega), fluorescence-activated cell
sorting analysis of DNA content, BrdU incorporation assay, Ki67 staining, and
detection of apoptosis by TUNEL assay are techniques routinely performed in
our laboratory (16, 24, 33, 39–41). Pull-down assays to evaluate H-Ras activity
were performed using at least 3 mg of protein and GST-Raf (plasmid no. 13338;
Addgene) (42).
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